Amylyx Pharmaceuticals resumes AMX0114 clinical trials for ALS after FDA clears path
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Phase 1 trial ... Read More
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More
Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS
RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More